ETFChannel.com
RCUS Description — Arcus Biosciences Inc

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. Co. has four clinical-stage investigational products: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB154, which promotes sustained immune activation and tumor clearance in combination with proven immunotherapy strategies; Zimberelimab, which enables the development of precision combination regimens with full line-of-sight to the commercialization of therapies for all patients; and AB680, which is a potent and selective small-molecule to provide differential benefits relative to monoclonal antibodies.

Company Name: 
Arcus Biosciences Inc
Website: 
www.arcusbio.com
Sector: 
Biotechnology
Number of ETFs Holding RCUS: 
26
Total Market Value Held by ETFs: 
$218,776,938.41
Total Market Capitalization: 
$2,382,000,000
% of Market Cap. Held by ETFs: 
9.18%
 ETF   RCUS Weight   RCUS Amount 
 XBI   0.91%   $65,836,865         
 VTI   0.00%   $49,106,842         
 IWM   0.05%   $35,690,769         
 VXF   0.02%   $22,644,124         
 IWN   0.11%   $17,023,675         
 IBB   0.11%   $11,797,196         
 VHT   0.02%   $4,296,406         
 VTWO   0.05%   $3,506,763         
 LABU   0.49%   $3,246,410         
 ITOT   0.00%   $1,501,076         
List of all 26 ETFs holding RCUS »
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding RCUS | Arcus Biosciences Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.